Feature | March 16, 2015

New Research Shows PCI Benefits STEMI Patients Even After 12 Hours

Late-presenting patients show same results as early presenters

Minneapolis Heart Institute Foundation, PCI, STEMI, late presenters

March 16, 2015 — New research from the Minneapolis Heart Institute Foundation (MHIF) finds that percutaneous coronary intervention for heart attacks can still be beneficial for patients who get to their more than 12 hours after their chest pain has started. Timothy Henry, M.D., lead MHIF researcher and director of cardiology at Cedars-Sinai Medical Center in Los Angeles, presented the study results at the 2015 American College of Cardiology (ACC) conference in San Diego.

Almost 250,000 Americans experience ST-elevated myocardial infarction (STEMI), the deadliest form of heart attack, each year. Many of these patients are treated with percutaneous coronary intervention (PCI, or coronary artery stenting) within 90 minutes of getting to a medical center — a guideline recommended by the American Heart Association. But treatment guidelines have been less clear for patients who get to a medical center late — more than 12 hours after their chest pain has started. “Despite previous studies showing PCI improves survival for these late presenters,” said Henry, “management of these patients continues to be controversial.”

To further study the impact of PCI on STEMI patients who receive later treatment, Henry and a team of MHIF researchers examined prospective data from 3,157 patients in the Level 1 regional STEMI program at the Minneapolis Heart Institute at Abbott Northwestern Hospital from March 2003 to March 2014. They placed the patients into three groups: those that arrived at a medical center within 6 hours of chest pain starting (“early presenters”), those arriving within 6–12 hours, and those arriving 12–24 hours after the start of pain (“late presenters”).

The death rate (in-hospital, at 30 days, and at 1 year) and length of hospital stay for late presenters (6.7 percent of patients) was similar to that of early presenters. “Our research supports the use of primary PCI in late presenters,” stated Henry. “Although the door to balloon time was longer for late presenters, the clinical benefits of PCI were similar to those who received earlier treatment.”

For more information: www.mplsheart.org

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init